VISTA

Essex Bio-Technology Posts Sound 2023 Annual Financial Results, Revenue Up 29.5%, Profit Up 22.1%

Retrieved on: 
Monday, March 18, 2024
Cloud, Research, SKQ1, Quality control, Weather, NMPA, Therapeutic Goods Administration, Environment, Best, Intelligence, Patent, Patient, Conditional sentence, Ophthalmology, Hospital, POCT, Acquisition, CMC, European Medicines Agency, GMP, City, QMS, Bevacizumab, Chemistry, Yoy, US FDA, Traction, Good, Therapy, Point-of-care testing, VISTA, Pharmaceutical industry

The Group weathered the headwinds and managed to deliver sound performances amidst the challenging trading environment in 2023.

Key Points: 
  • The Group weathered the headwinds and managed to deliver sound performances amidst the challenging trading environment in 2023.
  • As of 31 December 2023, the Group had cash and cash equivalents of approximately HK$509.8 million (2022: approximately HK$543.5 million).
  • Together with the interim dividend of HK$0.045 per ordinary share paid on 13 September 2023, the total dividend for 2023 would be HK$0.09 (2022: HK$0.065) per ordinary share.
  • The Group's turnover is primarily made up of the ophthalmology segment ("Ophthalmology") and surgical (wound care and healing) segment ("Surgical").

Sensei Biotherapeutics to Participate in Canaccord Genuity’s Horizons in Oncology Virtual Conference

Retrieved on: 
Tuesday, April 9, 2024
NEXT, Therapy, Patient, Conference, Canaccord Genuity, VISTA, Cancer

BOSTON, April 09, 2024 (GLOBE NEWSWIRE) --  Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, today announced that Company management will participate in a panel titled ‘KRAS and VISTA - Better Approaches for Key Targets’ at Canaccord Genuity’s Horizons in Oncology Virtual Conference on Monday, April 15th at 2:00 p.m.

Key Points: 
  • BOSTON, April 09, 2024 (GLOBE NEWSWIRE) --  Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, today announced that Company management will participate in a panel titled ‘KRAS and VISTA - Better Approaches for Key Targets’ at Canaccord Genuity’s Horizons in Oncology Virtual Conference on Monday, April 15th at 2:00 p.m.
  • ET.
  • The panel will feature Dr. Shiraj Sen, M.D., Ph.D., Medical Oncologist and Director of Clinical Research at NEXT Oncology-Dallas.
  • Dr. Sen is an investigator on the ongoing Phase 1/2 clinical trial for SNS-101.

Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial

Retrieved on: 
Monday, April 8, 2024
Combination, CPI, Immunosuppression, Patient, Tumor microenvironment, Immunoglobulin G, Merck, Cancer, Pembrolizumab, Lung cancer, AACR, DLT, Clinical trial, Merck & Co., Kineta, NK, VISTA, Pharmaceutical industry

SEATTLE, April 08, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today at the American Association for Cancer Research (AACR) in San Diego, CA an update on its ongoing VISTA-101 Phase 1/2 clinical trial evaluating KVA12123, an anti-VISTA monoclonal antibody, as monotherapy and in combination with Merck’s anti-PD1 therapy, KEYTRUDA® (pembrolizumab), in patients with advanced solid tumors.

Key Points: 
  • KVA12123 cleared the fifth of six monotherapy dose levels and the second of four cohorts in combination with pembrolizumab.
  • KVA12123 was well tolerated with no dose limiting toxicities (DLT) or cytokine related adverse events at any dose level.
  • Patients currently enrolled in the trial will be permitted to continue to participate.
  • KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment

Retrieved on: 
Thursday, April 4, 2024
Risk, Sensei, Patient, Research, Tumor microenvironment, Manuscript, CRS, Cancer, Trial of the century, Cytokine release syndrome, Myelocyte, Antibody, Safety, Therapy, VISTA, Nature Communications, PD-1, Vaccine

The research was conducted by scientists at Sensei Biotherapeutics in collaboration with genOway and the laboratory of Dr. Robert Schreiber at the Washington University, St. Louis School of Medicine.

Key Points: 
  • The research was conducted by scientists at Sensei Biotherapeutics in collaboration with genOway and the laboratory of Dr. Robert Schreiber at the Washington University, St. Louis School of Medicine.
  • The paper describes Sensei Biotherapeutics’ approach to the discovery and development of SNS-101, which was designed to potently and selectively target the active protonated form of VISTA, a protein that plays a significant role in suppressing T-cell activation.
  • SNS-101 is designed to block VISTA by inhibiting its interaction with PSGL-1 on T-cells resulting in T-cell activation.
  • The manuscript published in Nature Communications is entitled “VISTA checkpoint inhibition by pH-selective antibody SNS-101 with optimized safety and pharmacokinetic profiles enhances PD-1 response,” and can be found here: https://rdcu.be/dDF8x

Sensei Biotherapeutics to Participate in the 3rd Annual VISTA Symposium

Retrieved on: 
Friday, March 22, 2024
Sensei, Therapy, Patient, Webcast, Cancer, VISTA, Broadcasting

BOSTON, March 22, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, today announced that Company management will participate on a panel titled ‘Anti-VISTA Immunotherapies in Clinical Development’ at the 3rd Annual VISTA Symposium.

Key Points: 
  • BOSTON, March 22, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, today announced that Company management will participate on a panel titled ‘Anti-VISTA Immunotherapies in Clinical Development’ at the 3rd Annual VISTA Symposium.
  • The VISTA Symposium will convene scientific experts and industry leaders to explore the important emerging role of VISTA in cancer immunotherapy and will review the latest insights on VISTA biology, the growing potential of VISTA as a therapeutic target in multiple cancer indications and share updates on the ongoing clinical development of anti-VISTA therapies.
  • The symposium will take place virtually on Wednesday, March 27 from 11 a.m. to 3:30 p.m.
  • A webcast of Sensei’s presentation will be available in the Investors section of the Sensei website.

Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, March 21, 2024
Research, Combination, CPI, AML, Caregiver, Bone marrow, Insurance, Patient, Merck, Acute myeloid leukemia, Cancer, Public expenditure, Pembrolizumab, Lung cancer, Trial of the century, Cytokine release syndrome, AACR, Chemokine, Clinical trial, Annual report, Safety, Workforce, Infrared spectroscopy correlation table, NK, VISTA, Pharmaceutical industry

SEATTLE, March 21, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company with a mission to develop next-generation immunotherapies that transform patients’ lives, announced today financial results for the full year ended December 31, 2023 and provided a corporate update.

Key Points: 
  • In February 2024, the Company announced a significant corporate restructuring to substantially reduce expenses and preserve cash.
  • We truly appreciate the efforts of the healthcare professionals, the patients and their caregivers, and the Kineta employees involved in this trial.
  • Announced positive KVA12123 monotherapy safety data from its ongoing Phase 1/2 VISTA-101 clinical trial in patients with advanced solid tumors.
  • Cash position: As of December 31, 2023, cash was $5.8 million, compared to $13.1 million as of December 31, 2022.

NVIDIA Healthcare Launches Generative AI Microservices to Advance Drug Discovery, MedTech and Digital Health

Retrieved on: 
Monday, March 18, 2024
Nexus, Cloud, Hewlett Packard Enterprise, Azure, GTC, Google Cloud, Health, Metropolis, Patient, History, Orion, LLM, Therapy, San Jose Convention Center, Microsoft, Synthetic media, Vanilla, SAN, Oracle Cloud, 3D, AUC, Protein folding, AWS, Chemistry, Hippocrates, Flywheel, Amgen, Data management, Drug discovery, Acceleration, Hospital, Cadence, AI, Medtech, Dell Technologies, Amazon Web Services, API, CPU, VISTA, Supermicro, Biology, NIM, Universal, Collection, NVIDIA, Generative, Medical device

The microservices, 25 of which launched today, can accelerate transformation for healthcare companies as generative AI introduces numerous opportunities for pharmaceutical companies, doctors and hospitals.

Key Points: 
  • The microservices, 25 of which launched today, can accelerate transformation for healthcare companies as generative AI introduces numerous opportunities for pharmaceutical companies, doctors and hospitals.
  • These include screening for trillions of drug compounds to advance medicine, gathering better patient data to aid early disease detection and implementing smarter digital assistants.
  • “By helping healthcare companies easily build and manage AI solutions, we’re enabling them to harness the full power and potential of generative AI.”
    The new suite of healthcare microservices includes NVIDIA NIM , which provides optimized inference for a growing collection of models across imaging, medtech, drug discovery and digital health.
  • Hippocratic AI is developing task-specific Generative AI Healthcare Agents, powered by the company’s safety-focused LLM for healthcare, connected to NVIDIA Avatar Cloud Engine microservices and will utilize NVIDIA NIM for low-latency inferencing and speech recognition.

Utah Sports Commission Presents Tony Hawk's Vert Alert Road to X Games

Retrieved on: 
Thursday, March 21, 2024
Top Ten, University of Utah, University, Female, FREE, Athlete, Male, Wild Cards, VISTA

VISTA, Calif., March 21, 2024 /PRNewswire/ -- Today, the Utah Sports Commission, Tony Hawk Inc., and X Games announced an incredible weekend of skateboarding featuring "Tony Hawk's Vert Alert (THVA)," to take place at the Jon M. Huntsman Center at the University of Utah on Friday, June 14th and Saturday, June 15th, 2024. After incredibly successful Vert Alert events in 2021-2023, Tony Hawk and X Games continue their relationship, with Tony Hawk's Vert Alert serving as a direct qualifying event leading to X Games 2024.

Key Points: 
  • After incredibly successful Vert Alert events in 2021-2023, Tony Hawk and X Games continue their relationship, with Tony Hawk's Vert Alert serving as a direct qualifying event leading to X Games 2024.
  • Also on Friday is the incredibly popular Tony Hawk's Vert Alert "Legends Demo."
  • "We're thrilled to host Tony Hawk's Vert Alert event, presented by the Utah Sports Commission, at our Jon M. Huntsman Center," said Aaron White Director Stadium & Arena Event Services for University of Utah.
  • Entry to the Jon M. Huntsman Center and access to "Tony Hawk's Vert Alert" will be FREE to the general public on both days.

Vista Bank Will Soon Open the Doors to Fair Park's First New Bank in Almost Three Decades

Retrieved on: 
Wednesday, March 13, 2024
Organization, Community development, Small business, Partnership, Trust, Social Security, LPO, Bank, Education, DEC, Boy, SDFP, Carter High School, Quality of life, Athlete, Student, Commerce, System, COMMUNITY, MLK BLVD, I-30, Family, DISD, VISTA, Vista Bank, Vista

"Vista Bank's commitment to our community…will drastically raise the quality of life for so many."

Key Points: 
  • "Vista Bank's commitment to our community…will drastically raise the quality of life for so many."
  • With over a century of West Texas roots, the Bank expanded its footprint into Dallas in 2017 with a loan production office (LPO.)
  • Vista would eventually open a full-service location in Preston Center, where the headquarters were relocated in early 2020.
  • "I am beyond thrilled that Vista Bank has announced the opening of a Branch in South Dallas," stated Dallas City Councilman Adam Bazaldua.

Hummingbird Bioscience and Dartmouth's Geisel School of Medicine to Co-Host 3rd Annual Virtual VISTA Symposium on March 27, 2024

Retrieved on: 
Wednesday, March 13, 2024
DVM, Head, Q&A, Entrepreneurship, Immunotherapy, Patient, Triple-negative breast cancer, Immunology, Geisel School of Medicine, Columbia University, Cancer, Doctor of Philosophy, MD, Lung cancer, Yale School of Medicine, Neoplasm, Physician, VISTA, Management

SINGAPORE and HANOVER, Germany, March 13, 2024 /PRNewswire/ -- Hummingbird Bioscience and Dartmouth's Geisel School of Medicine today announced that the 3rd Annual VISTA Symposium will take place virtually on Wednesday, March 27, 2024 (11:00 AM - 3:30 PM ET).

Key Points: 
  • SINGAPORE and HANOVER, Germany, March 13, 2024 /PRNewswire/ -- Hummingbird Bioscience and Dartmouth's Geisel School of Medicine today announced that the 3rd Annual VISTA Symposium will take place virtually on Wednesday, March 27, 2024 (11:00 AM - 3:30 PM ET).
  • High VISTA expression in tumor correlates with poor survival in cancer patients and has been associated with a lack of response to other immune checkpoint inhibitors.
  • Pre-clinical data on VISTA biology and VISTA targeting have shown potent anti-tumor effects, and clinical readouts are expected this year.
  • The symposium will explore the important role of VISTA in cancer immunotherapy.